• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Procaps Group S.A.

    12/31/24 6:01:21 AM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PROC alert in real time by email
    6-K 1 ea0226337-6k_procaps.htm 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549 

     

     

     

    FORM 6-K

     

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

     

     

    For the month of December

     

    2024 Commission File Number: 001-40851 

     

     

     

    Procaps Group, S.A.

    (Translation of registrant’s name in English) 

     

     

     

    9 rue de Bitbourg, L-1273

    Luxembourg

    Grand Duchy of Luxembourg

    R.C.S. Luxembourg: B253360

    Tel : +356 7995-6138

    (Address of Principal Executive Offices)

     

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒          Form 40-F ☐

     

     

     

     

     

    INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

     

    Appointment of Interim CFO

     

    As previously disclosed by Procaps Group, S.A. (the “Company”), effective December 19, 2024, the Company appointed an Interim Chief Financial Officer to focus on the restatement process and financial reporting, including the preparation and signing of the company’s 2023 and 2024 financial statements and Annual Reports on Form 20-F. On December 27, 2024, the Board of Directors (the “Board”) of the Company formally appointed Daniel Bernal as the Interim Chief Financial Officer (“Interim CFO”). Mr. Bernal was appointed as Interim CFO in connection with the Company’s engagement of Moore Colombia to assist the Company with respect to the finalization of its financial statements.

     

    Mr. Daniel Bernal is a Managing Partner of Moore Colombia, a consulting firm that provides specialized consulting services across a wide range of professional services, a position he has held since 2022. In his role as Managing Partner, Mr. Bernal is responsible for the design and control of Moore Colombia’s operation of each of the professional service areas provided. Mr. Bernal has over 29 years of experience working in a host of multinational and national professional services firms. Prior to his position as Managing Partner at Moore Colombia, from 2020 to 2022, Mr. Bernal was a Managing Partner at Audit Business Enterprise, a firm that provides auditing and business process outsourcing services, and from 1998 to 2020, an Audit Partner at Deloitte & Touche, a professional services firm. Mr. Bernal holds a degree in Public Accounting from Santo Tomas de Aquino University and is a certified public accountant in Colombia. Additionally, Mr. Bernal holds certificates in IFRS standards, international auditing standards, and PCAOB accounting standards.

     

    Other than as discussed above, there are no arrangements or understandings between Mr. Bernal and any other person pursuant to which Mr. Bernal was appointed as Interim CFO of the Company. In addition, since the beginning of the Company’s last fiscal year, there are no family relationships between Mr. Bernal and any director or executive officer of the Company, and Mr. Bernal does not have any other direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 7B of Form 20-F.

     

    Issuance of Additional Convertible Note

     

    As previously disclosed by the Company, on November 29, 2024, the Company entered into a Secured Convertible Note Subscription Agreement (the “NSA”) with Hoche Partners Pharma Holdings S.A., an entity controlled by Alejandro Weinstein, the Company’s Chairman of the Board (“Hoche”), pursuant to which the Company may issue up to $40 million in Secured Convertible Notes (the “Convertible Notes”) to Hoche pursuant to the terms and conditions therein, of which an aggregate of $20 million in Convertible Notes were issued on November 29, 2024.

     

    As previously disclosed, pursuant to the NSA and subject to certain limited exceptions, Hoche had the obligation to subscribe for and purchase an additional Convertible Note in principal amount of $20 million on or prior to December 29, 2024 (the “Second Note”). On December 27, 2024, the Company issued the Second Note to Hoche and received an additional $20 million in gross proceeds.

     

    The Convertible Notes bear interest at an annual rate of 8.50%, payable in-kind, quarterly in arrears, and mature on June 30, 2025. All accrued and unpaid interest due at the end of each such quarterly period shall be paid in kind by capitalizing such interest and adding it to (and thereby increasing) the then-outstanding principal amount of the Convertible Notes. Other key terms of the Convertible Notes were previously disclosed by the Company on a Form 6-K filed by the Company with the Securities and Exchange Commission on December 3, 2024.

     

    The sale and issuance of the Convertible Notes pursuant to the NSA have not been, and any future sale and/or issuance of ordinary shares of the Company will not be, registered under the Securities Act or any state securities laws. The securities may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Neither this Report on Form 6-K, nor the exhibits attached hereto, is an offer to sell or the solicitation of an offer to buy the securities described herein or therein.

      

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      PROCAPS GROUP, S.A.
         
      By: /s/ José Antonio Toledo Vieira  
      Name: José Antonio Toledo Vieira  
      Title: Chief Executive Officer

     

    Dated: December 31, 2024

     

     

     

    Get the next $PROC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PROC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PROC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Procaps Group Receives Delisting Notice From Nasdaq

      MIAMI and BARRANQUILLA, Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that the Company received a notice from The Nasdaq Stock Market LLC ("Nasdaq") that it has determined to delist the Company's ordinary shares on Nasdaq. The delisting is a result of the Company's failure to demonstrate compliance with Nasdaq Listing Rules 5250(c)(1) and 5250(c)(2) for failing to file periodic and interim financial reports. As a result of the forgoing, the Company's ordinary shares are expected to commence trading on the Expert Market operated by the OTC

      2/3/25 8:50:00 AM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Procaps Group Receives Additional Delinquency Letter

      MIAMI and BARRANQUILLA, Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that, as anticipated, on December 31, 2024, the Company received notice from The Nasdaq Stock Market LLC ("Nasdaq") of an additional filing delinquency relating to the Company's interim financial statements for the period ended June 30, 2024. The interim financial statements were required to be filed with Nasdaq by December 31, 2024, but were not for the reasons previously disclosed in connection with the delay in the filing of the Company's Form 20-F for the fiscal yea

      1/3/25 4:15:00 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates

      MIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team. The Shareholders Meeting marked an important milestone with the election of new members to the Board of Directors. The newly elected members bring a diverse range of expertise and strategic insight to guide Procaps' future growth. Newly app

      12/20/24 4:53:03 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PROC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Manieu Alexandre Weinstein claimed ownership of 15,877,516 units of Ordinary Shares

      3 - Procaps Group, S.A. (0001863362) (Issuer)

      10/12/21 9:32:55 AM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Minski Ruben claimed ownership of 31,338,454 units of Ordinary Shares

      3 - Procaps Group, S.A. (0001863362) (Issuer)

      10/8/21 5:22:21 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Minski Jose claimed ownership of 17,960,146 units of Ordinary Shares

      3 - Procaps Group, S.A. (0001863362) (Issuer)

      10/8/21 5:20:55 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PROC
    SEC Filings

    See more
    • SEC Form 6-K filed by Procaps Group S.A.

      6-K - Procaps Group, S.A. (0001863362) (Filer)

      2/19/25 8:56:19 AM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Procaps Group S.A.

      6-K - Procaps Group, S.A. (0001863362) (Filer)

      2/3/25 9:00:03 AM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Procaps Group S.A.

      6-K - Procaps Group, S.A. (0001863362) (Filer)

      1/16/25 8:30:04 AM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PROC
    Leadership Updates

    Live Leadership Updates

    See more
    • Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates

      MIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team. The Shareholders Meeting marked an important milestone with the election of new members to the Board of Directors. The newly elected members bring a diverse range of expertise and strategic insight to guide Procaps' future growth. Newly app

      12/20/24 4:53:03 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Statement from the Board of Directors of Procaps Group

      Procaps Group (NASDAQ:PROC) ("Procaps"). Having completed the last ordinary meeting of 2023 on December 19th in which Ruben Minski acted as CEO of the Procaps Group for the last time, and taking into account that as of January 15th, 2024 he will take over as Executive Chairman of the Board, which resulted from a planned and communicated process to the market since February of this year, we would like to express our appreciation to Ruben for his inspiring and visionary leadership that has allowed Procaps to be a leading organization in the pharmaceutical sector in the Region today, recognized and valued in the market by the different stakeholders. Throughout his career in the Organization,

      12/21/23 6:45:00 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024

      Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today a strategic leadership transition as Ruben Minski, founder and CEO of Procaps prepares to transition from the role of Chief Executive Officer to focus exclusively on his role as Executive Chairman of the Board, and the appointment of Jose Antonio Vieira as the new Chief Executive Officer of Procaps Group. The transition will be effective January 15, 2024. After over 45 years of visionary leadership and dedicated service, Ruben Minski has played a pivotal role in Procaps' growth and success, transforming it into a global leader in pharmaceutical innovation. Under

      11/22/23 8:30:00 AM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PROC
    Financials

    Live finance-specific insights

    See more
    • Procaps Group Reports Third Quarter 2023 Results

      Net Revenues Increased 5% in 9M23 Year-over-Year on a Constant Currency Basis, Driven by 13% RX Growth Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated international healthcare and pharmaceutical services company, today announced its financial results for the three months ended September 30, 2023 ("3Q23") and the nine months ended September 30, 2023 ("9M23"). Financial Highlights 3Q23 & 9M23 Net revenues totaled $118 million for 3Q23, positively impacted by the performance of RX and OTC portfolios, offset by lower CDMO revenues. On a constant currency basis, net revenues increased by 2% in 3Q23. For 9M23, net revenues totaled $313 million, an incre

      12/26/23 5:40:00 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Procaps Group Update on Third Quarter Results

      Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it is postponing the previously-announced earnings conference call (currently scheduled for November 16, 2023) to a later date after Procaps publishes its results for the third quarter and nine months ended September 30, 2023 ("3Q23"). Procaps will host a conference call in conjunction with its release of the 3Q23 Results, and call/webcast details will be provided in advance of the call. About Procaps Group Procaps Group, S.A. ("Procaps") (NASDAQ:PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplie

      11/14/23 5:25:00 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Procaps Group to Report Third Quarter and Nine Months 2023 Results on Tuesday November 14, 2023

      Company to Host Conference Call on Thursday November 16, 2023 at 10:30 a.m. Eastern Time Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical services company, announced it will report its results for the third quarter and nine months ended September 30, 2023, after market closes on Tuesday, November 14, 2023. The Company will host a conference call and webcast on Thursday, November 16, 2023, at 10:30 a.m. Eastern time, to discuss the third quarter and nine months 2023 results. To access the call, please use the following information: Date: Thursday, November 16, 2023 Time: 10:30 a.m. ET Webcast: Cli

      11/10/23 11:37:00 AM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PROC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

      SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

      12/3/24 7:20:10 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

      SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

      10/29/24 9:46:26 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

      SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

      10/28/24 8:42:14 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care